Why Kidney Diets Must Be Individualized for Chronic Kidney Disease

Deep-research Food-as-Medicine article on chronic kidney disease, asking why kidney diets must be individualized rather than copied from a single diet sheet. CDC Chronic Kidney Disease in the United States, 2023 (via NIDDK, verified live 2026-11-09) estimates CKD in 35.5 million U.S. adults (14%), in about 20% of non-Hispanic Black adults versus about 12% of non-Hispanic White adults, with more than 808,000 people living with end-stage kidney disease (USRDS 2023). The 2020 KDOQI nutrition guideline (Ikizler 2020, PMID 32829751) organizes kidney nutrition as dietitian-delivered medical nutrition therapy across stages 1-5, dialysis, and transplant; its expert commentary (Kistler 2021, PMID 32737016) states protein ranges of 0.55-0.6 g/kg/day without diabetes and 0.6-0.8 g/kg/day with diabetic kidney disease. In non-diabetic CKD, a Cochrane synthesis of 17 trials (n=2,996; Hahn 2020, PMID 33118160) found low protein (0.5-0.6 g/kg/day) made little difference to reaching end-stage kidney disease versus normal protein (RR 1.05, 95% CI 0.73-1.53), while very low protein (0.3-0.4 g/kg/day) probably reduced progression in advanced disease (RR 0.65, 95% CI 0.49-0.85), with harms and quality of life barely measured. Salt reduction in CKD lowered blood pressure by -6.91/-3.91 mm Hg with high certainty across 21 studies (McMahon 2021, PMID 34164803), and by 10/4 mm Hg in a 20-person crossover trial (McMahon 2013, PMID 24204003), while also increasing symptomatic hypotension (RR 6.70). A plant-dominant low-protein framework (0.6-0.8 g/kg/day, >50% plant sources; Kalantar-Zadeh 2020, PMID 32610641) is presented as a framework, not a trial result, and a potassium literature review (AlSahow 2023, PMID 37766841) found a lack of strong evidence for intense potassium restriction and recommended individualized, gradual, stepwise reduction. No product is named or recommended; kidney disease gives no supplement recommendation without clinician or pharmacist review. Evidence grade: MODERATE. Educational article from the Buddha Ayurvedic School of Medicine: https://buddha.hospital

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-09
DOI
https://doi.org/10.5281/zenodo.24085584
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Why Kidney Diets Must Be Individualized for Chronic Kidney Disease

Ajarn Shaman Shu
Zenodo (CERN European Organization for Nuclear Research)
Dialysis and Renal Disease Management
article

Why Kidney Diets Must Be Individualized for Chronic Kidney Disease

Ajarn Shaman Shu
article en

Abstract

Deep-research Food-as-Medicine article on chronic kidney disease, asking why kidney diets must be individualized rather than copied from a single diet sheet. CDC Chronic Kidney Disease in the United States, 2023 (via NIDDK, verified live 2026-11-09) estimates CKD in 35.5 million U.S. adults (14%), in about 20% of non-Hispanic Black adults versus about 12% of non-Hispanic White adults, with more than 808,000 people living with end-stage kidney disease (USRDS 2023). The 2020 KDOQI nutrition guideline (Ikizler 2020, PMID 32829751) organizes kidney nutrition as dietitian-delivered medical nutrition therapy across stages 1-5, dialysis, and transplant; its expert commentary (Kistler 2021, PMID 32737016) states protein ranges of 0.55-0.6 g/kg/day without diabetes and 0.6-0.8 g/kg/day with diabetic kidney disease. In non-diabetic CKD, a Cochrane synthesis of 17 trials (n=2,996; Hahn 2020, PMID 33118160) found low protein (0.5-0.6 g/kg/day) made little difference to reaching end-stage kidney disease versus normal protein (RR 1.05, 95% CI 0.73-1.53), while very low protein (0.3-0.4 g/kg/day) probably reduced progression in advanced disease (RR 0.65, 95% CI 0.49-0.85), with harms and quality of life barely measured. Salt reduction in CKD lowered blood pressure by -6.91/-3.91 mm Hg with high certainty across 21 studies (McMahon 2021, PMID 34164803), and by 10/4 mm Hg in a 20-person crossover trial (McMahon 2013, PMID 24204003), while also increasing symptomatic hypotension (RR 6.70). A plant-dominant low-protein framework (0.6-0.8 g/kg/day, >50% plant sources; Kalantar-Zadeh 2020, PMID 32610641) is presented as a framework, not a trial result, and a potassium literature review (AlSahow 2023, PMID 37766841) found a lack of strong evidence for intense potassium restriction and recommended individualized, gradual, stepwise reduction. No product is named or recommended; kidney disease gives no supplement recommendation without clinician or pharmacist review. Evidence grade: MODERATE. Educational article from the Buddha Ayurvedic School of Medicine: https://buddha.hospital

Zenodo (CERN European Organization for Nuclear Research)
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon